Ruxolitinib phosphate

SKU: orb1304597

Description

Research Area

Cardiovascular Research, Cell Biology, Epigenetics & Chromatin, Signal Transduction, Stem Cell & Developmental Biology

Images & Validation

−

Key Properties

−

CAS Number	1092939-17-7
MW	404.36
Purity	99.86%
Formula	C₁₇H₂₁N₆O₄P
SMILES	OP(O)(O)=O.N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12
Target	Autophagy,JAK,Mitophagy
Solubility	H2O:8 mg/mL (19.78 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (12.37 mM);DMSO:250 mg/mL (618.26 mM)

Bioactivity

−

Target IC50	JAK3:428 nM\|Tyk2:19 nM\|JAK1:3.3 nM\|JAK2:2.8 nM
In Vivo	METHODS: Mouse aortic vascular smooth musclee cells (VSMC), treated with ruxolitinib ( nM, 1 nM, 5 nM and 10 nM) for 24 hours or 48 hours or pretreated with ruxolitinib ( nM, 1 nM, 5 nM and 10 nM) or AG490 (5 μM) 6 hours, and then treated with or without platelet-derived growth factor-BB (PDGF-BB) (20 ng/mL) for a Other 24 hours, and Western Blot blotting was performed to detec the levels of JAK2 and STAT3. Result the cell viability of PDGF-BB-treated VSMCs was reduced when treated with Ruxolitinib. Ruxolitinib partially inhibite the growth of VSMC cells by targetin the JAK2/STAT3 signaling pathway. Read more...
In Vitro	METHODS: Mouse aortic vascular smooth musclee cells (VSMC), treated with ruxolitinib ( nM, 1 nM, 5 nM and 10 nM) for 24 hours or 48 hours or pretreated with ruxolitinib ( nM, 1 nM, 5 nM and 10 nM) or AG490 (5 μM) 6 hours, and then treated with or without platelet-derived growth factor-BB (PDGF-BB) (20 ng/mL) for a Other 24 hours, and Western Blot blotting was performed to detec the levels of JAK2 and STAT3. Result the cell viability of PDGF-BB-treated VSMCs was reduced when treated with Ruxolitinib. Ruxolitinib partially inhibite the growth of VSMC cells by targetin the JAK2/STAT3 signaling pathway. Read more...
Cell Research	Ruxolitinib phosphate is dissolved in 0.2% DMSO. Cells are seeded at 2000/well of white bottom 96-well plates, treated with compounds from DMSO stocks (0.2% final DMSO concentration , and incubated for 48 hours at 37℃ith 5% CO2. Viability is measured by cellular ATP determination usin the Cell-Titer Glo luciferase reagent or viable cell counting. Values are transformed to percent Inhibition relative to Vehicle control, and IC50 curves are fitted according to nonlinear regression analysis o the data using PRISM GraphPad. Read more...

Storage & Handling

−

Storage	keep away from direct sunlight,keep away from moisture,store under nitrogen \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Inhibitor, Janus kinase, JAK2, JAK, JAK1, inhibit, INCB 018424, INCB 018424 Phosphate, INC 424, INC 424 phosphate, INC 424 Phosphate, INC424, INC-424, INC424 Phosphate, INC-424 Phosphate, INCB018424, INCB-018424, INCB018424 Phosphate, INCB018424 phosphate, INCB-018424 Phosphate, Mitophagy, Mitochondrial Autophagy, Autophagy, Ruxolitinib, Ruxolitinib (INCB-18424) phosphate, Ruxolitinib (INCB-18424) Phosphate, Ruxolitinib Phosphate, Ruxolitinib phosphate

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

25127112 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols